Philogen
PHIL | XMIL
Overview
Corporate Details
- ISIN(s):
- IT0005373789 (+1 more)
- LEI:
- 81560009EA1577917768
- Country:
- Italy
- Address:
- PIAZZA LA LIZZA, 7, 53100 SIENA
- Website:
- https://www.philogen.com
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
Founded in 1996, Philogen is an Italian-Swiss biotechnology company engaged in the discovery and development of biopharmaceutical products for the treatment of life-threatening conditions. Philogen Group mainly discovers and develops targeted anti-cancer drugs, exploiting high-affinity ligands for tumor markers. These ligands – namely human monoclonal antibodies or small molecules – are identified through Antibody Phage Display Libraries and DNA-Encoded Chemical Libraries technologies. The main therapeutic strategy of the Group for the treatment of these diseases is the so-called “tumor targeting”.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-07-07 16:50 |
Transaction in Own Shares
2025 07 07 - CS settimanale acquisto azioni proprie
|
Italian | 153.0 KB | |
| 2025-07-07 12:08 |
Regulatory News Service
Allegato 3F
|
Italian | 26.7 KB | |
| 2025-06-30 17:04 |
Transaction in Own Shares
2025 06 30 - CS settimanale acquisto azioni proprie
|
Italian | 181.7 KB | |
| 2025-06-25 12:29 |
Regulatory News Service
Philogen Provides Update on Marketing Authorization Application for Nidlegy™ in…
|
English | 180.5 KB | |
| 2025-06-11 01:34 |
Regulatory News Service
Press Release Licenza OncoACP3 (Price Sensitive)
|
Italian | 225.0 KB | |
| 2025-06-03 13:40 |
Transaction in Own Shares
2025 06 03 - CS settimanale acquisto azioni proprie
|
Italian | 144.1 KB | |
| 2025-05-26 17:46 |
Share Issue/Capital Change
Statuto
|
Italian | 261.6 KB | |
| 2025-05-26 17:24 |
AGM Report
Deposito del Verbale dell'Assemblea degli Azionisti
|
Italian | 131.0 KB | |
| 2025-05-26 17:22 |
General Meeting Notice
Verbale dei lavori dell'Assemblea Ordinaria e Straordinaria degli Azionisti
|
Italian | 30.4 MB | |
| 2025-05-26 15:09 |
Transaction in Own Shares
2025 05 26 - CS settimanale acquisto azioni proprie
|
Italian | 147.5 KB | |
| 2025-05-19 12:24 |
Transaction in Own Shares
2025 05 19 - CS settimanale acquisto azioni proprie
|
Italian | 130.7 KB | |
| 2025-05-12 15:04 |
Transaction in Own Shares
2025 05 12 - CS settimanale acquisto azioni proprie
|
Italian | 141.2 KB | |
| 2025-05-07 10:30 |
Transaction in Own Shares
Allegato 3F
|
Italian | 27.5 KB | |
| 2025-05-06 18:56 |
Interim Report
Il Consiglio di Amministrazione approva la posizione finanziaria netta relativa…
|
Italian | 259.8 KB | |
| 2025-04-29 18:05 |
AGM Report
Comunicato stampa Assemblea 29 aprile 2025
|
Italian | 209.6 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
1NKEMIA | Spain | IKM | |
|
2cureX AB | Sweden | 2CUREX | |
|
4SC AG | Germany | VSC | |
|
Abera Bioscience AB | Sweden | ABERA | |
|
ABIONYX Pharma | France | ABNX | |
|
Abliva | Sweden | ABLI | |
|
AB Science | France | AB | |
|
Acticor Biotech | France | ALACT | |
|
Active Biotech | Sweden | ACTI | |
|
AcuCort AB | Sweden | ACUC |